carbidopa/levodopa / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 61 Diseases   27 Trials   27 Trials   880 News 


«12...3456789101112131415»
  • ||||||||||  Trial completion date, Trial primary completion date:  Gait Analysis in Neurological Disease (clinicaltrials.gov) -  Jan 2, 2020   
    P=N/A,  N=120, Recruiting, 
    Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Oct 2019 --> Oct 2020
  • ||||||||||  citalopram / Generic mfg., carbidopa/levodopa / Generic mfg.
    Trial completion, Enrollment change, Trial completion date:  SELEIS: Effect of Serotonin and Levodopa in Ischemic Stroke (clinicaltrials.gov) -  Nov 26, 2019   
    P4,  N=39, Completed, 
    Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Oct 2019 --> Oct 2020 Recruiting --> Completed | N=240 --> 39 | Trial completion date: Dec 2018 --> Oct 2019
  • ||||||||||  carbidopa/levodopa / Generic mfg., naproxen ER / Generic mfg., naproxen / Generic mfg.
    Enrollment change:  Effect of L-dopa In Subacute Back Pain Population (clinicaltrials.gov) -  Sep 25, 2019   
    P4,  N=72, Completed, 
    We report the first evidence of potential anti-parkinsonian efficacy of the oral selective D1/D5 partial agonist PF-06412562 without the significant acute changes in cardiovascular parameters reported with previous D1 agonists. N=125 --> 72
  • ||||||||||  carbidopa/levodopa / generics
    Restless Genital Syndrome in a patient with Dementia with Lewy Body (Agora 2 West, Level 2) -  Sep 24, 2019 - Abstract #MDSCongress2019MDS_340;    
    It is important to keep RGS in mind –however rare- in any case with unexplained genital discomfort sensations. A dopamine agonist agent would be of benefit in relieving these symptoms.
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Carbidopa-Levodopa in Dry AMD With Geographic Atrophy (clinicaltrials.gov) -  Sep 17, 2019   
    P2,  N=7, Active, not recruiting, 
    A dopamine agonist agent would be of benefit in relieving these symptoms. Recruiting --> Active, not recruiting | N=254 --> 7 | Trial completion date: Mar 2020 --> Mar 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Inbrija (levodopa inhalation powder) / Acorda
    Journal:  Inhaled levodopa (Inbrija) for Parkinson's disease. (Pubmed Central) -  Aug 6, 2019   
    Recruiting --> Active, not recruiting | N=254 --> 7 | Trial completion date: Mar 2020 --> Mar 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 No abstract available
  • ||||||||||  PF-06412562 / Pfizer, Cerevel Therap
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  PF 06412562 in Subjects With Advanced Stage Parkinson's Disease (clinicaltrials.gov) -  Jul 30, 2019   
    P1,  N=8, Completed, 
    No abstract available Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2019 | Trial primary completion date: Dec 2019 --> Mar 2019
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Enrollment open:  ESTREL: Enhancement of Stroke Rehabilitation With Levodopa (clinicaltrials.gov) -  Jun 17, 2019   
    P3,  N=610, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2019 | Trial primary completion date: Dec 2019 --> Mar 2019 Not yet recruiting --> Recruiting
  • ||||||||||  carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
    Enrollment change, Trial termination:  Vision Response to Dopamine Replacement (clinicaltrials.gov) -  Jun 12, 2019   
    P2,  N=20, Terminated, 
    Not yet recruiting --> Recruiting N=50 --> 20 | Recruiting --> Terminated; Lack of funding
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome (clinicaltrials.gov) -  Apr 22, 2019   
    P=N/A,  N=10, Completed, 
    No abstract available Enrolling by invitation --> Completed | N=15 --> 10 | Trial completion date: Nov 2019 --> Feb 2019 | Trial primary completion date: Nov 2018 --> Feb 2019
  • ||||||||||  PF-06412562 / Pfizer, Cerevel Therap
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  PF 06412562 in Subjects With Advanced Stage Parkinson's Disease (clinicaltrials.gov) -  Apr 18, 2019   
    P1,  N=8, Active, not recruiting, 
    Enrolling by invitation --> Completed | N=15 --> 10 | Trial completion date: Nov 2019 --> Feb 2019 | Trial primary completion date: Nov 2018 --> Feb 2019 Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Dec 2019 | Trial primary completion date: Mar 2019 --> Dec 2019
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial completion date, Trial primary completion date:  Dose Ranging Study of Carbidopa-levodopa (clinicaltrials.gov) -  Apr 7, 2019   
    P2,  N=52, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Dec 2019 | Trial primary completion date: Mar 2019 --> Dec 2019 Trial completion date: Feb 2019 --> Feb 2021 | Trial primary completion date: Dec 2018 --> Dec 2020
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial completion date, Trial primary completion date:  Carbidopa-levodopa in Neovascular AMD (clinicaltrials.gov) -  Apr 7, 2019   
    P2,  N=52, Recruiting, 
    Trial completion date: Feb 2019 --> Feb 2021 | Trial primary completion date: Dec 2018 --> Dec 2020 Trial completion date: Feb 2019 --> Feb 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial completion date, Trial primary completion date:  Extension, Carbidopa-levodopa in Neovascular AMD (clinicaltrials.gov) -  Apr 5, 2019   
    P2,  N=52, Recruiting, 
    Trial completion date: Feb 2019 --> Feb 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Mar 2019 --> Mar 2021 | Trial primary completion date: Dec 2018 --> Dec 2020
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Biomarker, Enrollment change, Trial withdrawal, Metastases:  A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration (clinicaltrials.gov) -  Apr 5, 2019   
    P2,  N=0, Withdrawn, 
    Trial completion date: Mar 2019 --> Mar 2021 | Trial primary completion date: Dec 2018 --> Dec 2020 N=104 --> 0 | Suspended --> Withdrawn
  • ||||||||||  Biomarker, Trial completion date, Trial primary completion date:  Measuring Parkinson's Disease Progression (clinicaltrials.gov) -  Mar 26, 2019   
    P1,  N=40, Recruiting, 
    N=104 --> 0 | Suspended --> Withdrawn Trial completion date: Feb 2019 --> Sep 2019 | Trial primary completion date: Feb 2019 --> Sep 2019
  • ||||||||||  PF-06412562 / Pfizer, Cerevel Therap
    Trial completion date, Trial primary completion date, Metastases:  PF 06412562 in Subjects With Advanced Stage Parkinson's Disease (clinicaltrials.gov) -  Feb 18, 2019   
    P1,  N=8, Recruiting, 
    Trial completion date: Feb 2019 --> Sep 2019 | Trial primary completion date: Feb 2019 --> Sep 2019 Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2019
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Enrollment open, Phase classification:  L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults (clinicaltrials.gov) -  Jan 17, 2019   
    P4,  N=90, Recruiting, 
    Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2019 Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4
  • ||||||||||  Trial primary completion date:  Gait Analysis in Neurological Disease (clinicaltrials.gov) -  Dec 12, 2018   
    P=N/A,  N=110, Recruiting, 
    Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 Trial primary completion date: Oct 2018 --> Oct 2019
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Enrollment open, Trial initiation date:  Carbidopa-Levodopa in Dry AMD With Geographic Atrophy (clinicaltrials.gov) -  Sep 6, 2018   
    P2,  N=254, Recruiting, 
    Trial primary completion date: Oct 2018 --> Oct 2019 Not yet recruiting --> Recruiting | Initiation date: Apr 2018 --> Jul 2018
  • ||||||||||  Enrollment change:  Gait Analysis in Neurological Disease (clinicaltrials.gov) -  Dec 14, 2017   
    P=N/A,  N=100, Recruiting, 
    Not yet recruiting --> Completed | N=78 --> 150 N=60 --> 100
  • ||||||||||  Biomarker, Phase classification, Trial initiation date:  Measuring Parkinson's Disease Progression (clinicaltrials.gov) -  Nov 6, 2017   
    P1,  N=40, Recruiting, 
    N=60 --> 100 Phase classification: P=N/A --> P1 | Initiation date: Jul 2017 --> Oct 2017
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Enrollment open:  Extension, Carbidopa-levodopa in Neovascular AMD (clinicaltrials.gov) -  Oct 23, 2017   
    P2,  N=52, Recruiting, 
    Phase classification: P=N/A --> P1 | Initiation date: Jul 2017 --> Oct 2017 Not yet recruiting --> Recruiting
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial primary completion date:  Dose Ranging Study of Carbidopa-levodopa (clinicaltrials.gov) -  Oct 23, 2017   
    P2,  N=52, Recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  carbidopa/levodopa / Generic mfg.
    Trial primary completion date:  Carbidopa-levodopa in Neovascular AMD (clinicaltrials.gov) -  Oct 23, 2017   
    P2,  N=52, Recruiting, 
    Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  carbidopa/levodopa / Generic mfg., naproxen ER / Generic mfg., naproxen / Generic mfg.
    Trial completion, Trial primary completion date:  Effect of L-dopa In Subacute Back Pain Population (clinicaltrials.gov) -  Oct 11, 2017   
    P4,  N=125, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017
  • ||||||||||  carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse (clinicaltrials.gov) -  Sep 27, 2017   
    P2,  N=131, Completed, 
    Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017 Recruiting --> Completed | N=90 --> 131 | Trial primary completion date: Aug 2017 --> Jan 2017
  • ||||||||||  ODM-104 / Orion Corp
    Trial completion:  Pharmacokinetic of Levodopa Study in Healthy Males (clinicaltrials.gov) -  Sep 26, 2017   
    P1,  N=20, Completed, 
    Recruiting --> Completed | N=90 --> 131 | Trial primary completion date: Aug 2017 --> Jan 2017 Active, not recruiting --> Completed
  • ||||||||||  citalopram / Generic mfg., carbidopa/levodopa / Generic mfg.
    Trial primary completion date:  SELEIS: Effect of Serotonin and Levodopa in Ischemic Stroke (clinicaltrials.gov) -  Aug 14, 2017   
    P4,  N=240, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Mar 2017
  • ||||||||||  ODM-104 / Orion Corp
    Enrollment closed:  Pharmacokinetic of Levodopa Study in Healthy Males (clinicaltrials.gov) -  Jul 31, 2017   
    P1,  N=20, Active, not recruiting, 
    Trial primary completion date: Dec 2016 --> Mar 2017 Recruiting --> Active, not recruiting